Viagra is a well-known medication primarily used to treat erectile dysfunction (ED) in men. It has been available since 1998 and has helped millions of men improve their sexual function.
Sildenafil is the active ingredient in Viagra. It is also found in the medication Revatio, which is used to treat pulmonary hypertension. Sildenafil helps to increase blood flow to the penis, allowing men to achieve and maintain an erection during sexual stimulation.
Viagra belongs to a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors. These medications work by helping to relax muscles and arteries inside the penis, allowing for increased blood flow and improved erectile function.
Erectile dysfunction, or impotence, is the inability to get or keep an erection firm enough for sexual intercourse. Viagra is approved for the treatment of ED in males aged 18 years and older. The medication has been shown to be effective in improving erectile function in men with various underlying health conditions, including diabetes, heart disease, and high blood pressure.
Viagra is approved for use in males ages 18 years and older. It is not intended for use in children or adolescents under the age of 18.
Sildenafil, the active ingredient in Viagra, is also used to treat pulmonary hypertension. This condition is characterized by high blood pressure in the blood vessels leading to the lungs. Revatio, a medication containing sildenafil, is prescribed for this purpose and can be taken by most adults and children aged 1 year and over.
Most adults and children aged 1 year and over can take sildenafil for the treatment of pulmonary hypertension. However, it is essential to consult with a healthcare professional to determine the appropriate dosage and ensure the medication is safe for use in specific populations.
Sildenafil is not suitable for everyone.
Individuals should consult their doctor or pharmacist before taking sildenafil if they have ever had an allergic reaction to sildenafil or any other medication, are taking nitrates for chest pain (angina), or have a serious heart or liver problem.Additionally, sildenafil should not be taken by those with certain eye diseases (such as retinitis pigmentosa), sickle cell anemia, leukemia, multiple myeloma, or deformities of the penis (like Peyronie's disease).
Viagra can interact with certain medications, such as nitrates used to treat angina. Combining these medications can lead to a dangerous drop in blood pressure. It is crucial to discuss all medications and supplements with a healthcare professional before starting Viagra or any other PDE5 inhibitor.
Individuals with pre-existing health conditions, such as heart problems, liver problems, stroke, or a recent heart attack, should exercise caution when considering the use of Viagra. Consultation with a healthcare professional is essential to determine if the medication is appropriate and safe to use.
It is crucial to consult with a healthcare professional before using Viagra or any other medication for erectile dysfunction or pulmonary hypertension. A prescription is required for both Viagra and generic sildenafil, which can be obtained either in person or online through telehealth services. Always follow the advice of your healthcare provider to ensure the safe and effective use of these medications.
16 AUGUST 2011: OUTCOME OF ARHA’S EXTRAORDINARY GENERAL MEETING
An Extraordinary General Meeting of the members of the Australian Reproductive Health Alliance (ARHA) was held on Monday August 15th 2011.
The meeting was convened to consider the resolution that, in view of the continuing financial insecurity facing the Alliance and the decision of the Parliamentary Group on Population and Development to transfer its Secretariat to another organisation, the Australian Reproductive Health Alliance cease on September 30th 2011.
The motion was passed unanimously and ARHA will cease to exist in any form after that date.
The decision to close an organisation which has achieved so much over the past 15 years was taken in sadness. The Management Committee of ARHA would like to thank all those members and supporters who have sustained us in so many ways over that time.
For more information please do not hesitate to contact Susan Stratigos, ARHA President, on +61 (0)2 6278 6948 or 0402 957 259.
Member of ACFID & Signatory to the ACFID Code of Conduct.
NGO Special Consultative Status with the Economic and Social Council of the United Nations